FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989109314> ?p ?o ?g. }

• W1989109314 endingPage "iv12" @default.
• W1989109314 startingPage "iv12" @default.
• W1989109314 abstract "Background: The role of downstream targets of the EGFR pathway and of p53 as biomarker in patients (pts) with advanced pancreatic cancer (APC) has not yet been defined. Methods: Within the phase III study AIO-PK0104 281 pts with APC were randomized between gemcitabine/erlotinib followed by capecitabine and capecitabine/erlotinib followed by gemcitabine. Archival formalin fixed paraffin embedded tissue was used to conduct central immunohistochemistry (IHC) staining for pERK (n = 153), pAKT (n = 35) and p53 (n = 50) expression. A semi-quantitative IHC scoring system considering the cytoplasmic and nuclear expression (staining intensity & % of positive cells) was developed for pERK (score 0-12) and pAKT (score 0-12). The IHC expression status of the tumor-suppressor gene p53 was assessed as a categorical variable (complete loss, regular expression, and overexpression). Within a retrospective, hypothesis-generating subgroup analysis, biomarker data (either as dichotomous or continuous variable) were correlated with efficacy endpoints and skin rash using a Cox regression model. Results: 98/153 pts were classified as pERKhigh (score 6-12) and 55/153 pts as pERKlow; median OS was 5.7 months in pERKhigh pts and 6.2 months in pERKlow pts (HR 1.29, 95% CI 0.90-1.83, p = 0.16). When analysing pERK as continuous variable, a significant association between the pERK score and OS was found (HR 1.06, 95% CI 1.0-1.12, p [log rank] = 0.050, p [likelihood ratio] = 0.047), indicating an increase in the hazard for death by a factor of 1.06 for each score level of pERK expression. 14/35 pts were classified as pAKThigh (score 5-12) and 21/35 pts as pAKTlow; median OS was 6.8 months in pAKThigh pts and 6.4 months in pAKTlow pts (HR 1.03, 95% CI 0.51-2.11, p = 0.93). Regarding p53, 4/50 pts had a complete loss of p53 expression, 20/50 pts a regular expression and 26/50 pts had tumors with a p53 overexpression, respectively. The p53 status had no impact on OS (global p value = 0.91), however a significant improvement in PFS (6.0 months vs. 1.8 months, HR 0.24, p = 0.02) and a higher rate of skin rash (84% vs. 25%, p = 0.02) was observed for pts with a regular p53 expression compared to pts with a complete loss of p53 in their tumor. Conclusion: pERK expression may have an impact on OS and the p53 status might be correlated with PFS (but not with OS) and the occurrence of skin rash in erlotinib-treated pts with APC. A prospective and external validation of these results is necessary." @default.
• W1989109314 created "2016-06-24" @default.
• W1989109314 creator A5011137037 @default.
• W1989109314 creator A5022323779 @default.
• W1989109314 creator A5023061535 @default.
• W1989109314 creator A5029807838 @default.
• W1989109314 creator A5031266401 @default.
• W1989109314 creator A5037754184 @default.
• W1989109314 creator A5047006205 @default.
• W1989109314 creator A5047331780 @default.
• W1989109314 creator A5049792647 @default.
• W1989109314 creator A5051987249 @default.
• W1989109314 creator A5052605376 @default.
• W1989109314 creator A5059278629 @default.
• W1989109314 creator A5063677056 @default.
• W1989109314 creator A5064981456 @default.
• W1989109314 creator A5066663298 @default.
• W1989109314 creator A5071888326 @default.
• W1989109314 creator A5090795046 @default.
• W1989109314 creator A5091422927 @default.
• W1989109314 date "2013-06-01" @default.
• W1989109314 modified "2023-10-17" @default.
• W1989109314 title "P-ERK, P-AKT and p53 as Tissue Biomarkers in Erlotinib-Treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From Aio-PK0104" @default.
• W1989109314 doi "https://doi.org/10.1093/annonc/mdt201.3" @default.
• W1989109314 hasPublicationYear "2013" @default.
• W1989109314 type Work @default.
• W1989109314 sameAs 1989109314 @default.
• W1989109314 citedByCount "1" @default.
• W1989109314 countsByYear W19891093142014 @default.
• W1989109314 crossrefType "journal-article" @default.
• W1989109314 hasAuthorship W1989109314A5011137037 @default.
• W1989109314 hasAuthorship W1989109314A5022323779 @default.
• W1989109314 hasAuthorship W1989109314A5023061535 @default.
• W1989109314 hasAuthorship W1989109314A5029807838 @default.
• W1989109314 hasAuthorship W1989109314A5031266401 @default.
• W1989109314 hasAuthorship W1989109314A5037754184 @default.
• W1989109314 hasAuthorship W1989109314A5047006205 @default.
• W1989109314 hasAuthorship W1989109314A5047331780 @default.
• W1989109314 hasAuthorship W1989109314A5049792647 @default.
• W1989109314 hasAuthorship W1989109314A5051987249 @default.
• W1989109314 hasAuthorship W1989109314A5052605376 @default.
• W1989109314 hasAuthorship W1989109314A5059278629 @default.
• W1989109314 hasAuthorship W1989109314A5063677056 @default.
• W1989109314 hasAuthorship W1989109314A5064981456 @default.
• W1989109314 hasAuthorship W1989109314A5066663298 @default.
• W1989109314 hasAuthorship W1989109314A5071888326 @default.
• W1989109314 hasAuthorship W1989109314A5090795046 @default.
• W1989109314 hasAuthorship W1989109314A5091422927 @default.
• W1989109314 hasBestOaLocation W19891093141 @default.
• W1989109314 hasConcept C121608353 @default.
• W1989109314 hasConcept C126322002 @default.
• W1989109314 hasConcept C143998085 @default.
• W1989109314 hasConcept C185592680 @default.
• W1989109314 hasConcept C204232928 @default.
• W1989109314 hasConcept C207103383 @default.
• W1989109314 hasConcept C2777909004 @default.
• W1989109314 hasConcept C2778087573 @default.
• W1989109314 hasConcept C2779438470 @default.
• W1989109314 hasConcept C2780210213 @default.
• W1989109314 hasConcept C2780258809 @default.
• W1989109314 hasConcept C2781197716 @default.
• W1989109314 hasConcept C44249647 @default.
• W1989109314 hasConcept C526805850 @default.
• W1989109314 hasConcept C55493867 @default.
• W1989109314 hasConcept C71924100 @default.
• W1989109314 hasConceptScore W1989109314C121608353 @default.
• W1989109314 hasConceptScore W1989109314C126322002 @default.
• W1989109314 hasConceptScore W1989109314C143998085 @default.
• W1989109314 hasConceptScore W1989109314C185592680 @default.
• W1989109314 hasConceptScore W1989109314C204232928 @default.
• W1989109314 hasConceptScore W1989109314C207103383 @default.
• W1989109314 hasConceptScore W1989109314C2777909004 @default.
• W1989109314 hasConceptScore W1989109314C2778087573 @default.
• W1989109314 hasConceptScore W1989109314C2779438470 @default.
• W1989109314 hasConceptScore W1989109314C2780210213 @default.
• W1989109314 hasConceptScore W1989109314C2780258809 @default.
• W1989109314 hasConceptScore W1989109314C2781197716 @default.
• W1989109314 hasConceptScore W1989109314C44249647 @default.
• W1989109314 hasConceptScore W1989109314C526805850 @default.
• W1989109314 hasConceptScore W1989109314C55493867 @default.
• W1989109314 hasConceptScore W1989109314C71924100 @default.
• W1989109314 hasLocation W19891093141 @default.
• W1989109314 hasLocation W19891093142 @default.
• W1989109314 hasOpenAccess W1989109314 @default.
• W1989109314 hasPrimaryLocation W19891093141 @default.
• W1989109314 hasRelatedWork W150304519 @default.
• W1989109314 hasRelatedWork W2036821810 @default.
• W1989109314 hasRelatedWork W2039578267 @default.
• W1989109314 hasRelatedWork W2057074797 @default.
• W1989109314 hasRelatedWork W2084590458 @default.
• W1989109314 hasRelatedWork W2097393212 @default.
• W1989109314 hasRelatedWork W2163866397 @default.
• W1989109314 hasRelatedWork W2184836338 @default.
• W1989109314 hasRelatedWork W2468249644 @default.
• W1989109314 hasRelatedWork W2187801383 @default.
• W1989109314 hasVolume "24" @default.
• W1989109314 isParatext "false" @default.
• W1989109314 isRetracted "false" @default.

• next